pharma · Lymphoma of B-cell origin · Malignant Solid Tumors
Genmab
Genmab A/S
Genmab clinical programs — 29 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Carl Jacobsens Vej 30, 2500 Valby, DK
- Employees
- 2,847
- Programs
- 29
- Drugs
- 56
- Patents
- 0
Genmab projects
29 ClinicalTrials.gov programs sponsored by Genmab.
Genmab has 29 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
GCT1046-06
Genmab A/S
Non-Small Cell Lung Cancer
1 trial -
GCT1184-02
Genmab A/S
Platinum-resistant Ovarian Cancer
1 trial -
GCT1184-03
Genmab A/S
Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresectable Endometrial Cancer
1 trial -
GCT3013-05
Genmab A/S
B-cell Lymphoma
1 trial -
Rina-S
Genmab A/S
Ovarian Cancer
1 trial -
Epcoritamab for DIFFUSE LARGE B CELL LYMPHOMA
Genmab A/S
DIFFUSE LARGE B CELL LYMPHOMA
1 trial -
GCT1015-05
Genmab A/S
Recurrent or stage IVB cervical cancer
1 trial -
GCT1042-01
Genmab A/S
Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).
1 trial -
GCT1046-01
Genmab A/S
Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.
1 trial -
GCT1046-04
Genmab A/S
Malignant Solid Tumors - Non Small Cell Lung Cancer
1 trial -
GCT1046-07
Genmab A/S
Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)
1 trial -
GCT1055-01
Genmab A/S
Malignant Solid Tumors
1 trial -
GCT3013-01
Genmab A/S
Lymphoma of B-cell origin
1 trial -
GCT3013-02
Genmab A/S
Lymphoma of B-cell origin
1 trial -
GCT3013-03
Genmab A/S
Chronic Lymphocytic Leukemia
1 trial -
GCT3014-01
Genmab A/S
Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Large B Cell Lymphoma (DLBCL) Acute Myeloid Leukemia (AML)
1 trial -
GEN1042 DP, PEMBROLIZUMAB
Genmab A/S
Metastatic Solid Malignant tumors
1 trial -
GEN1047 DP
Genmab A/S
Malignant Solid Tumors
1 trial -
GEN1078 DP
Genmab A/S
Malignant solid tumors
1 trial -
GEN3014
Genmab A/S
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
PEGFILGRASTIM , Rinatabart Sesutecan
Genmab A/S
Locally advanced or metastatic Non-Small Cell Lung Cancer
1 trial -
Pembrolizumab
Genmab A/S
Advanced Endometrial Cancer
1 trial -
tisotumab vedotin
Genmab A/S
Solid Tumor
1 trial -
A Study of GEN1106 in Participants with Solid Tumors
Genmab A/S
Metastatic or advanced malignant solid tumors
1 trial -
GCT1056-01
Genmab A/S
Advanced solid tumors
1 trial -
GCT1057-01
Genmab A/S
Metastatic or advanced malignant solid tumors
1 trial -
GCT1079-01
Genmab A/S
Advanced Malignant Solid Tumors
1 trial -
GCT3018-01
Genmab A/S
Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
1 trial -
GEN1042
Genmab A/S
Malignant Solid Tumor
1 trial
Frequently asked questions
How many clinical projects does Genmab have?
29 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.